KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Accounts Payables (2016 - 2026)

Gsk has reported Accounts Payables over the past 18 years, most recently at -$19.3 billion for Q1 2026.

  • For Q1 2026, Accounts Payables fell 1.29% year-over-year to -$19.3 billion; the TTM value through Mar 2026 reached -$19.3 billion, down 1.29%, while the annual FY2025 figure was -$20.5 billion, 203.95% down from the prior year.
  • Accounts Payables for Q1 2026 was -$19.3 billion at Gsk, up from -$20.5 billion in the prior quarter.
  • Over five years, Accounts Payables peaked at $19.7 billion in Q4 2024 and troughed at -$21.2 billion in Q3 2025.
  • A 5-year average of -$11.4 billion and a median of -$18.6 billion in 2022 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: soared 79.07% in 2022 and later tumbled 311.35% in 2023.
  • Year by year, Accounts Payables stood at $19.1 billion in 2022, then increased by 3.09% to $19.7 billion in 2023, then increased by 0.09% to $19.7 billion in 2024, then tumbled by 203.95% to -$20.5 billion in 2025, then grew by 5.54% to -$19.3 billion in 2026.
  • Business Quant data shows Accounts Payables for GSK at -$19.3 billion in Q1 2026, -$20.5 billion in Q4 2025, and -$21.2 billion in Q3 2025.